Dr. Naomi Sacks, Vice President, HEORStrategies, a Division of ToxStrategies LLC, is at the annual meeting of ISPOR (The Professional Society for Health Economics and Outcomes Research), which is being held in Atlanta May 5–8, 2024. Dr. Sacks is a co-author on the poster presentation, “Treatment History, Healthcare Resource Use, and Costs Among Patients with Pulmonary Arterial Hypertension (PAH) Initiating Treatment with Macitentan: A Retrospective Claims Analysis.” If you are at ISPOR, reach out to Naomi!

https://www.ispor.org/conferences-education/conferences/upcoming-conferences/ispor-2024

HEORStrategies’ scientist Dr. Naomi Sacks, along with clinicians and industry leaders, is presenting results of a study of antibiotic treatment patterns and treatment failure (TF) in uncomplicated UTI (uUTI) in the US at the 2024 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), held in Barcelona April 27-30. In this study, Sacks and colleagues analyzed US healthcare claims data and found that uUTI patients with treatment failure had higher rates of UTI recurrence, and that patient demographics, including older age and clinical risk factors, may be associated with the risk of TF and recurrent UTI.

HEORStrategies is excited to be attending, exhibiting, and hosting a round table at the World Orphan Drug Congress (WODC), April 23–25, 2024. This year’s congress is at the Boston Convention and Exhibit Center.

Come by and see us at Booth 537!

Also, join us at Roundtable 06, on Wednesday, April 24, at 14:15, when our experts will discuss, “Meeting the Challenges of Fast-Track Approval for Orphan Drugs.” HEORStrategies Vice President, Naomi Sacks, PhD, will be joined by colleagues from ToxStrategies, Modality Solutions, and EpidStrategies to focus on optimal strategies for managing fast-track approval, from pre-clinical through clinical phases of development, regulatory support, and launch.